Abstract Number: 2634 • 2017 ACR/ARHP Annual Meeting
The Prevalence of Autoimmune Disease in Families of Patients with Systemic Lupus Erythematosus (SLE). a Single Centre Study
Background/Purpose: Studies to date have reported that up to 30% of lupus patient have a first degree relative with an autoimmune disorder (AD). The most…Abstract Number: 1328 • 2017 ACR/ARHP Annual Meeting
A Dual ICOS/CD28 Antagonist ICOSL Variant Ig Domain (vIgDTM) Potently Suppresses Mouse Collagen-Induced Arthritis and Human Xenograft Graft Vs. Host Disease (GvHD)
Background/Purpose: Our proprietary variant Ig domain (vIgD) platform creates novel, therapeutically-applicable protein domains with tailored specificity and affinity. These vIgDs are created through directed…Abstract Number: 2740 • 2017 ACR/ARHP Annual Meeting
Cyclophosphamide Treatment Modulates Circulating Cell Populations in Patients with Vasculitis and Autoimmune Systemic Diseases
Background/Purpose: Although cyclophosphamide (CFA) remain the cornerstone for treatment of patients with severe manifestations of systemic autoimmune diseases, the knowledge about the effect of CFA…Abstract Number: 1407 • 2017 ACR/ARHP Annual Meeting
Huntingtin Interactin Protein 1 (HIP1) Regulates Invasiveness, Actin Filament and Lamellipodia Formation in Rheumatoid Arthritis Fibroblast-like Synoviocytes (FLS)
Background/Purpose: Huntingtin-interacting protein 1 (Hip1) is an arthritis severity and joint damage gene recently discovered in rodent models of arthritis. Hip1 regulates fibroblast-like synoviocytes (FLS)…Abstract Number: 2826 • 2017 ACR/ARHP Annual Meeting
Fine-Mapping Identifies Causal Variants for RA and T1D in DNASE1L3, Sirpg, MEG3, TNFAIP3 and CD28/CTLA4 Loc
Background/Purpose: While genome-wide association studies have identified risk loci for rheumatoid arthritis and other autoimmune diseases, in very few instances have causal variants driving risk…Abstract Number: 152 • 2017 Pediatric Rheumatology Symposium
Characteristics of Patients With Juvenile Idiopathic Arthritis in a US Healthcare Claims Database
Background/Purpose: Abatacept, the first selective co-stimulation modulator approved and used for the treatment of juvenile idiopathic arthritis (JIA), has a mechanism of action that is…Abstract Number: 147 • 2017 Pediatric Rheumatology Symposium
Epigenetic and Transcriptomic Profiling of Primary Juvenile Idiopathic Arthritis Patient Cells: Better Understanding of Disease Pathogenesis
Background/Purpose: For many autoimmune diseases, including Juvenile Idiopathic Arthritis (JIA), the molecular mechanisms remain elusive. JIA can be used as a model to study autoimmune…Abstract Number: 12L • 2016 ACR/ARHP Annual Meeting
Efficacy and Safety of Atacicept in Patients with Systemic Lupus Erythematosus: Results of a 24-Week Randomized, Placebo-Controlled, Phase IIb Study
Background/Purpose: Atacicept targets B-cell stimulating factors BLyS and APRIL. In the APRIL-SLE trial, atacicept 150 mg was associated with reduced SLE flares in post-hoc analyses.1Methods:…Abstract Number: 1179 • 2016 ACR/ARHP Annual Meeting
The Impact of Autoimmune Disease in the Management and Prognosis of Acute Coronary Syndrome
Background/Purpose: Patients with autoimmune diseases (AID) have a high burden of cardiovascular disease leading to premature morbidity and mortality. But it is unclear if it…Abstract Number: 1244 • 2016 ACR/ARHP Annual Meeting
Establishing a Case Report Form (CRF) for Systemic Autoimmune Diseases Studies
Background/Purpose: Systemic autoimmune diseases (SADs) are heterogeneous conditions with peculiar characteristics that share several clinical features. It is suspected that SADs share similar molecular abnormalities,…Abstract Number: 1313 • 2016 ACR/ARHP Annual Meeting
Rheumatologic Diseases in HIV-Infected Patients in the Post-Antiretroviral Therapy Era: The County Experience
Background/Purpose: HIV infection has been associated with a plethora of rheumatologic diseases, however there are only few studies in the US analyzing the frequency of…Abstract Number: 1359 • 2016 ACR/ARHP Annual Meeting
New Markers for Celiac Disease: Anti-Neo-Epitope Human and Microbial Transglutaminases
Background/Purpose: Microbial transglutaminase (mTg) and human tissue Tg (tTg) complexed to gliadin peptides present neo-epitopes. Antibodies against these complexes are called tTg neo-epitope and mTg…Abstract Number: 1428 • 2016 ACR/ARHP Annual Meeting
Patient Attitudes Towards Being Prescribed Biosimilars in Inflammatory Autoimmune Diseases in Germany
Background/Purpose: Our aim is to address the lack of understanding surrounding patient attitudes to being prescribed biosimilars in the real world for Rheumatoid Arthritis (RA),…Abstract Number: 1610 • 2016 ACR/ARHP Annual Meeting
Safety, Tolerability, and Dose-Dependent Inhibition of T-Cell-Dependent Antibody Response with MEDI4920, a Novel, Engineered CD40L Antagonist: Results of a Single-Ascending Dose Study in Healthy Volunteers
Background/Purpose: The CD40L/CD40 co-stimulatory pathway is important for T-cell-dependent antibody production. Previous clinical programs with intact monoclonal antibodies against CD40L have been discontinued due to…Abstract Number: 1912 • 2016 ACR/ARHP Annual Meeting
A New Avenue of Immune Regulation Conferred By Self-Glycerophospholipids Via Mobilization and Migration of Myeloid-Derived Suppressor Cells
Background/Purpose: Lipids function as essential components of biological membranes, as signaling molecules, and as energy storage molecules. Glycerol-based phospholipids, called glycerophospholipids (GPL), are the most…
- « Previous Page
- 1
- …
- 72
- 73
- 74
- 75
- 76
- …
- 80
- Next Page »